

Edgar Filing: - Form

Form

Unknown document format

e=2>\$ million

% of sales

% change \$

\$ million

% of sales

Neurology

265.5

51.4

%

47.2

%

180.4

44.2

%

Reproductive Health

170.2

32.9

%

5.9

%

160.6

39.4

%

Growth & Metabolism

62.2

12.0

%

Edgar Filing: - Form

%	17.2
	53.0
% Others	13.0
	18.8
%	3.7
%	37.1
	13.7
%	3.4

Total sales (US\$ million)

\$	516.7
%	100
%	26.7
\$	407.8
%	100

Sales by geographic region

Edgar Filing: - Form

	Three Months Ended March 31, 2004			Three Months Ended March 31, 2003	
	\$ million	% of sales	% change \$	\$ million	% of sales
Europe	230.6	44.6%	27.0%	181.5	44.5%
North America	183.3	35.5%	22.9%	149.2	36.6%
Latin America	26.4	5.1%	70.6%	15.5	3.8%
Others	76.5	14.8%	24.1%	61.6	15.1%
<hr/>					
Total sales (US\$ million)	\$ 516.7	100%	26.7%	\$ 407.8	100%

-more-

TOP TEN PRODUCTS

	* TA	Three Months Ended March 31, 2004			Three Months Ended March 31, 2003	
		\$ million	% of sales	% change \$	\$ million	% of sales
Rebif®	MS	259.6	50.2%	48.2%	175.2	43.0%
Gonal-f®	RH	137.4	26.6%	12.6%	122.0	29.9%
Saizen®	Growth	40.7	7.9%	22.8%	33.1	8.1%
Serostim®	Wasting	21.5	4.2%	8.0%	19.9	4.9%
Novantrone®	MS/Oncology	15.3	3.0%	19.0%	12.8	3.1%
Pergonal®	RH	7.4	1.4%	(28.0%)	10.3	2.5%
Cetrotide®	RH	6.3	1.2%	12.4%	5.6	1.4%
Crinone®	RH	4.5	0.9%	(0.1%)	4.5	1.1%
Stilamin®	Other	4.1	0.8%	25.0%	3.3	0.8%
Ovidrel®	RH	3.9	0.8%	67.3%	2.3	0.6%

* Therapeutic Areas

RH = Reproductive Health Wasting = AIDS Wasting
MS = Multiple Sclerosis Growth = Growth Retardation
Oncology = Oncology

-more-

Consolidated Income Statements

Three months ended March 31	2004 *	% of		2003 *	% of
	US\$'000	Revenues	% change	US\$'000	Revenues
Revenues					
Product sales	516,713		26.7%	407,786	
Royalty and license income	40,378		16.6%	34,620	
Total Revenues	557,091	100.0%	25.9%	442,406	100.0%
Operating Expenses					
Cost of product sales	75,669		20.8%	62,631	
% of Sales	14.6%			15.4%	
Selling, general and administrative	184,203	33.1%	30.7%	140,916	31.9%
Research and development	126,199	22.7%	(1.4%)	127,937	28.9%
Other operating expense, net	54,871	9.8%	19.9%	45,751	10.3%
Total Operating Expenses	440,942	79.2%	16.9%	377,235	85.3%
Operating Income	116,149	20.8%	78.2%	65,171	14.7%
Financial income, net	9,034		35.7%	6,656	
Other income, net	4			226	
Total Non Operating Income, Net	9,038			6,883	
Income Before Taxes and Minority Interests	125,187	22.5%	73.7%	72,054	16.3%
Taxes	20,031			11,529	
Income Before Minority Interests	105,156			60,525	
Minority interests	(974)			365	
Net Income	106,130	19.1%	76.4%	60,160	13.6%

* Unaudited

	2004	2003	% Change
Basic Earnings per Share (in U.S. dollars)			
- Bearer shares	6.73	3.80	77.3%
- Registered shares	2.69	1.52	77.3%

Edgar Filing: - Form

- American depositary shares	0.17	0.09	77.3%
<hr/>			
Diluted Earnings per Share (in U.S. dollars)			
<hr/>			
- Bearer shares	6.71	3.79	77.0%
<hr/>			
- Registered shares	2.69	1.52	77.0%
<hr/>			
- American depositary shares	0.17	0.09	77.0%
<hr/>			

Basic earnings per share are calculated in accordance with IAS 33 (Earnings per Share) by dividing the net income of the group, US\$106.1 million (2003 US\$60.2 million), by an appropriate number of shares. This is 11,368,535 bearer shares (2003 11,443,975) and 11,013,040 registered shares (2003 11,013,040). The total weighted average equivalent number of bearer shares is 15,773,751 (2003 15,849,191) for the three months ended March 31, 2004. As each American depositary share represents ownership interest in one fortieth of a bearer share, basic and diluted earnings per American depositary share is calculated as one fortieth of the earnings per bearer share.

For diluted earnings per share, the total number of bearer shares is adjusted to assume conversion of all in the money share options granted to employees and directors and does not take into consideration the impact of the convertible bond because it is anti-dilutive. The number of bearer shares used to calculate diluted earnings per share is 11,403,634 (2003 11,451,180).

-more-

Consolidated Statements of Cash Flows

Three months ended March 31	2004 *	2003 *
	US\$'000	US\$'000
Cash Flows From Operating Activities		
Income before taxes and minority interests	125,187	72,054
Depreciation and amortization	33,204	34,498
Financial income	(16,864)	(12,087)
Financial expense	6,896	2,161
Other non-cash items	8,647	13,686
<hr/>		
Cash Flows From Operating Activities Before Working Capital Changes	157,070	110,312
<hr/>		
Working Capital Changes		
Trade accounts payable, other current liabilities and deferred income	19,332	74,800
Trade accounts receivable	(16,154)	(9,982)
Inventories	1,148	(22,638)
Prepaid expenses and other current assets	(20,817)	(6,200)
Taxes paid	(37,704)	(31,081)
<hr/>		

Edgar Filing: - Form

Net Cash Flows From Operating Activities	102,875	115,211
Cash Flows From Investing Activities		
Purchase of property, plant and equipment	(39,492)	(57,468)
Purchase of intangible and other long-term assets	(3,510)	(7,257)
Purchase of financial assets	(415,231)	(130,926)
Proceeds from sale of property, plant and equipment	2,954	2,220
Interest received	26,931	21,330
Net Cash Flows From Investing Activities	(428,348)	(172,101)
Cash Flows From Financing Activities		
Proceeds from issuance of share capital	10,333	13,090
Proceeds from exercises of stock options	318	159
Premiums received on written calls	--	384
Issuance of long-term financial debt	8,784	--
Purchase of treasury shares	(103,125)	(24,637)
Repayment of bank advances	(5,582)	(9,260)
Repayment of long-term debt	--	(1,517)
Other non-current liabilities	1,985	(4,308)
Interest paid	(1,894)	(1,102)
Net Cash Flows From Financing Activities	(89,181)	(27,191)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(1,489)	1,371
Net Decrease in Cash and Cash Equivalents	(416,143)	(82,710)
Cash and Cash Equivalents		
- Beginning of period	1,003,972	686,033
- End of period	587,829	603,323

* Unaudited

-more-

Consolidated Balance Sheets

As of	March 31, 2004 *	December 31, 2003
	US\$'000	US\$'000
Assets		
Current Assets		
Cash and cash equivalents	587,829	1,003,972
Short-term financial assets	572,149	434,810
Trade accounts receivable	325,742	318,388
Inventories	288,779	319,820

Edgar Filing: - Form

Prepaid expenses and other current assets	237,007	220,334
Total Current Assets	2,011,506	2,297,324
Non-Current Assets		
Property, plant and equipment	682,277	701,453
Long-term financial assets	1,382,371	1,104,333
Intangible assets	253,035	259,626
Deferred tax assets	168,264	169,693
Other long-term assets	38,562	39,174
Total Non-Current Assets	2,524,509	2,274,279
Total Assets	4,536,015	4,571,603
Liabilities		
Current Liabilities		
Trade and other payables	348,586	338,862
Short-term financial debts	44,925	51,224
Income taxes	123,556	146,086
Deferred income - current	47,300	47,200
Other current liabilities	155,460	170,019
Total Current Liabilities	719,827	753,391
Non-Current Liabilities		
Long-term financial debts	525,598	532,022
Deferred tax liabilities	15,935	15,919
Deferred income - non current	167,996	174,911
Provisions and other long-term liabilities	216,129	213,556
Total Non-Current Liabilities	925,658	936,408
Total Liabilities	1,645,485	1,689,799
Minority Interests		
Minority Interests	614	1,614
Shareholders' Equity		
Share capital	254,314	253,895
Share premium	1,019,681	1,002,991
Treasury shares	(257,578)	(157,642)
Retained earnings	1,775,830	1,669,700
Fair value and other reserves	32,751	22,711
Cumulative foreign currency translation adjustments	64,918	88,535
Total Shareholders' Equity	2,889,916	2,880,190

Total Liabilities, Minority Interests and Shareholders' Equity	4,536,015	4,571,603
--	-----------	-----------

* Unaudited

-more-

Consolidated Statements of Equity

	Share capital US\$'000	Share premium US\$'000	Treasury shares US\$'000	Retained earnings US\$'000	Fair value and other reserves US\$'000	Cumulative foreign currency translation adjustments US\$'000	Total US\$'000
Balance as of January 1, 2003	253,416	989,141	(126,460)	1,364,626	(44,807)	25,282	2,461,198
Issue of share capital to employees	435	12,480	3,571				16,486
Net income for 2003				60,162			60,162
Purchase of treasury shares			(24,637)				(24,637)
Revaluation adjustments					(6,705)		(6,705)
Foreign currency translation adjustments						13,381	13,381
Balance as of March 31, 2003 *	253,851	1,001,621	(147,526)	1,424,788	(51,512)	38,663	2,519,885

Balance as of January 1, 2004	253,895	1,002,991	(157,642)	1,669,700	22,711	88,535	2,880,190
Issue of share capital to employees	419	16,690	3,189				20,298
Net income for 2004				106,130			106,130
Purchase of treasury shares			(103,125)				(103,125)
Revaluation adjustments					10,040		10,040
Foreign currency translation adjustments						(23,617)	(23,617)
Balance as of March 31 2004 *	254,314	1,019,681	(257,578)	1,775,830	32,751	64,918	2,889,916

* Unaudited

-end-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SERONO S.A.
a Swiss corporation
(Registrant)

April 22, 2004

By: /s/ Allan Shaw

Name:	Allan Shaw
Title:	Chief Financial Officer
